<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03215446</url>
  </required_header>
  <id_info>
    <org_study_id>STEINBERG-GIRARD 2015</org_study_id>
    <nct_id>NCT03215446</nct_id>
  </id_info>
  <brief_title>Evaluate the Muscle Protection Effect of Sevoflurane Sedation in Vascular Surgery</brief_title>
  <acronym>PHAR</acronym>
  <official_title>Evaluation of Total (Pre and Post) Conditioning on Rhabdomyolysis of Sedation With Sevoflurane Versus Propofol in Vascular Surgery With Clamping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Halogenated anaesthetic agents (HAA) may induce protective processes by pre-conditioning the&#xD;
      myocardium. All of the literature shows that HAA induce pre-conditioning, thanks to a class&#xD;
      effect, and Sevoflurane is the most widely used today.&#xD;
&#xD;
      In humans, the protective effects of halogenated agents have principally been studied in&#xD;
      heart surgery and have shown encouraging clinical results. It seems that HAA induce both&#xD;
      pre-conditioning of the myocardium (early and late) and post conditioning.&#xD;
&#xD;
      Given these protective effects of HAA, in 2007, the American Heart Association (AHA)&#xD;
      recommended the use of HAA for anaesthesia maintenance in non-cardiac surgery in patients&#xD;
      with a high cardio-vascular risk. The aim of this study is to show a decrease in&#xD;
      rhabdomyolysis and tissue distress (kidneys, myocardium and liver), thanks to Sevoflurane&#xD;
      anaesthesia, in the post-operative period following vascular surgery with clamping&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 13, 2016</start_date>
  <completion_date type="Actual">October 19, 2018</completion_date>
  <primary_completion_date type="Actual">May 29, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline Creatine PhosphoKinase</measure>
    <time_frame>up to 24 hours post surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Vascular Surgery</condition>
  <arm_group>
    <arm_group_label>propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maintenance of anaesthesia with propofol</intervention_name>
    <arm_group_label>propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maintenance of anaesthesia with sevoflurane</intervention_name>
    <arm_group_label>sevoflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  persons who have provided written consent&#xD;
&#xD;
          -  patients over 18 years of age&#xD;
&#xD;
          -  patients undergoing scheduled vascular surgery with high clamping for:&#xD;
&#xD;
          -  Abdominal aortic aneurysm&#xD;
&#xD;
          -  suprapopliteal vascular bypass (aorto-bi-femoral, femoral trifurcation, ilio-femoral&#xD;
             or femoro-femoral, femoro-popliteal).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  persons without health insurance cover&#xD;
&#xD;
          -  patients younger than 18 years of age, pregnant or breast-feeding women and adults&#xD;
             under guardianship&#xD;
&#xD;
          -  patients with epilepsy&#xD;
&#xD;
          -  emergency surgery&#xD;
&#xD;
          -  patient presenting a contra-indication for Sevoflurane: hypersensitivity to&#xD;
             sevoflurane or to other halogenated anaesthetic agents, myopathy, hyper-eosinophilia,&#xD;
             immunoallergic hepatitis, known or suspected genetic predisposition to malignant&#xD;
             hyperthermia&#xD;
&#xD;
          -  patients presenting a contra-indication to the use of Propofol: known hypersensitivity&#xD;
             to propofol or to one of the constituents of the product, allergy to peanuts or soja&#xD;
&#xD;
          -  Patients presenting a contra-indication for sufentanil: hypersensitivity to sufentanil&#xD;
             or to opioids&#xD;
&#xD;
          -  Association with opioid agonists-antagonists or partial opioid antagonists&#xD;
&#xD;
          -  patients presenting a CI for the use of Cisatracurium: history of allergy or&#xD;
             hypersensitivity to cisatracurium or atracurium&#xD;
&#xD;
          -  patients presenting cardiac, respiratory, renal or kidney failure, hypovolemia, poor&#xD;
             general health&#xD;
&#xD;
          -  Patients with a risl of prolongation of the QT interval&#xD;
&#xD;
          -  Patients with end-stage renal failure - requiring dialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2017</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

